Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02481193
Other study ID # YZYY-610
Secondary ID
Status Completed
Phase Phase 3
First received June 10, 2015
Last updated June 22, 2015
Start date March 2013
Est. completion date January 2014

Study information

Verified date June 2015
Source Yangzhou No.1 People's Hospital
Contact n/a
Is FDA regulated No
Health authority China: Ethics Committee
Study type Interventional

Clinical Trial Summary

The purpose of this study is to investigate the effects of different doses of cisatracurium pretreatment on succinylcholine-induced fasciculations and postoperative myalgia.


Description:

Purpose: To investigate the effects of different doses of cisatracurium pretreatment on succinylcholine-induced fasciculations and postoperative myalgia.

Methods: Ninety patients scheduled for laparoscopic cholecystectomies were equally randomized into three groups to receive pretreatment of 0.005, 0.01, and 0.02 mg/kg cisatracurium, respectively. General anesthesia was induced 3.5 min later, train of four stimulation was monitored 4.5 min later, succinylcholine 1.5 mg/kg was injected 5 min later, and endotracheal intubation was implemented 6.5 min later. The side effects of cisatracurium, intensity of fasciculations, intubating conditions, time and extent to maximal depression of twitch and time for its recovery to 20% of control value, severity of myalgia at 24 h postoperatively, serum potassium before the induction, at the time of endotracheal intubation, and 5 min after intubation were recorded.


Recruitment information / eligibility

Status Completed
Enrollment 90
Est. completion date January 2014
Est. primary completion date January 2014
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 20 Years to 65 Years
Eligibility Inclusion Criteria:

- American Standards Association (ASA) physical status I or II patients scheduled for elective laparoscopic cholecystectomies with tracheal intubation requiring general anesthesia

- 20 - 65 years old

- without acid-base imbalance and electrolyte disturbance

- with normal hepatic and renal function

Exclusion Criteria:

- Patients with known hyperkalemia

- Patients with increased intraocular pressure

- Patients with increased intracranial pressure

- Patients with symptoms of gastroesophageal reflux

- Patients with anticipated airway difficulties

- Patients with malignant fever

- Patients with neuromuscular disease

- Patients with burn or crush injuries

- Patients with taking drugs known to alter the action of neuromuscular blockers

- Patients with with a body mass index exceeding 30

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Drug:
Cisatracurium
Different doses of cisatracurium pretreatment

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Yangzhou No.1 People's Hospital

Outcome

Type Measure Description Time frame Safety issue
Primary The presence of fasciculations After the injection of succinylcholine for 1.5 minutes Yes
Secondary Side effects of the pretreatment of cisatracurium At the time of three minutes after the pretreatment of cisatracurium Yes
Secondary The time to maximal depression of twitch From the time of 4.5 minutes after the pretreatment of cisatracurium for two minutes Yes
Secondary The extent to maximal depression of twitch From the time of 4.5 minutes after the pretreatment of cisatracurium for two minutes Yes
Secondary The time for twitch recovery to 20% of its control value From the time of 4.5 minutes after the pretreatment of cisatracurium for two minutes Yes
Secondary The grades of endotracheal intubation At intubating time Yes
Secondary The changes of serum potassium After entering the operating theater till the anesthesia induction, at intubating, and 5 min after intubation Yes
Secondary Myalgia at 24 hours postoperatively At 24 hours postoperatively Yes
See also
  Status Clinical Trial Phase
Withdrawn NCT03338114 - Study to Evaluate the Safety & Efficacy of FLX-787-ODT to Treat Fasciculations in Tongue and Upper or Lower Extremity Muscles Most Affected in Subjects With ALS Phase 1/Phase 2
Recruiting NCT05760976 - Median Effective Dose of Cisatracurium for the Prevention of Fasciculation Caused by the Injection of Succinylcholine N/A
Terminated NCT03334786 - Study to Evaluate Safety & Efficacy of FLX-787-ODT to Treat Fasciculations in Tongue and Appendicular Muscle in Adult Subjects With ALS Phase 1/Phase 2